Alpheus Medical

Alpheus Medical operates in the specialized neuro-oncology and therapeutic-device market, addressing glioblastoma through a drug-ultrasound combination rather than a conventional systemic drug alone. Its differentiation is the PoMA™ approach: 5-ALA-derived protoporphyrin IX is activated with proprietary low-intensity, defocused ultrasound, with the objective of concentrating activity in tumor tissue. The lead program has progressed to a randomized Phase 2b trial for newly diagnosed glioblastoma, while prior Phase 1/2 results focused on recurrent high-grade gliomas. This places the company beyond early discovery but still short of regulatory commercialization. The closest competitive context includes established glioblastoma modalities such as Novocure’s Optune and recurrent-disease drug approaches, although Alpheus Medical’s mechanism and outpatient drug-device model are distinct. Its $60.5 million Series B and investors including HealthQuest Capital, Samsara BioCapital, OrbiMed, and Action Potential Venture Capital indicate meaningful specialist-investor support, but clinical execution remains the primary determinant of market position.

Alpheus Medical’s growth trajectory shows a progression from early financing and platform development to clinical-stage execution. The company was founded in 2014 and accumulated nine financing rounds between 2017 and 2025, including three debt financings, two seed rounds, two Series A rounds, a venture round, and a $60.5 million Series B. The 2021 and 2022 Series A financings together added $30 million, while the 2025 Series B represented the clear capital inflection point. Clinical advancement followed: positive Phase 1/2 results for recurrent high-grade gliomas were announced in November 2024, and a Phase 2b trial for newly diagnosed glioblastoma began on Apr 9, 2026. The appointment of Imran Eba as CFO in June 2025 also suggests a shift toward financing, operational scaling, and later-stage development. The company continues to report a very small employee range of one to ten people, so capital deployment and hiring efficiency will be important. Public information does not establish enrollment pace, headcount growth, regulatory timing, or commercialization plans.